Healthcare


 Illuccix Progress in China Strengthens Telix’s Global Pathway

Illuccix Progress in China Strengthens Telix’s Global Pathway

December 22, 2025 12:35 PM AEDT| By Sam

Telix Pharmaceuticals advances its global imaging strategy as China study outcomes strengthen regulatory confidence and support broader adoption of precision diagnostics across key oncology markets.

 Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape

Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape

December 19, 2025 06:14 PM AEDT| By Sam

ResMed operates within the healthcare equipment sector, combining medical devices and digital platforms while maintaining visibility across major Australian indices.

 Memphasys and the ASX 300 Setting in the Local Healthcare Space

Memphasys and the ASX 300 Setting in the Local Healthcare Space

December 19, 2025 06:09 PM AEDT| By Sam

Memphasys released a corporate update on additional share quotation, reflecting standard disclosure practices within the Australian healthcare sector and the ASX framework.

 Prescient Therapeutics Advances Europe Trial Path for PTX

Prescient Therapeutics Advances Europe Trial Path for PTX

December 19, 2025 05:15 PM AEDT| By Sam

This article explores how Prescient Therapeutics is expanding its European clinical program, strengthening global research efforts, and advancing PTX development through regulated trial pathways.

 Ansell Limited’s Measured Approach to Debt and Stability

Ansell Limited’s Measured Approach to Debt and Stability

December 19, 2025 05:10 PM AEDT| By Sam

This article explores how Ansell Limited manages debt responsibly, supported by cash flow discipline, balance sheet strength, and long-term business fundamentals within the Australian equity landscape.

 Are SHL Shares at a Turning Point for Long-Term Watchers?

Are SHL Shares at a Turning Point for Long-Term Watchers?

December 19, 2025 05:04 PM AEDT| By Sam

An in-depth look at Sonic Healthcare and Xero, exploring business models, market positioning, and valuation perspectives shaping discussion across the Australian share market.

 Fresh Capital Update Signals Strategic Momentum at 4DMedical

Fresh Capital Update Signals Strategic Momentum at 4DMedical

December 19, 2025 04:06 PM AEDT| By Sam

An in-depth look at 4DMedical’s latest ASX share quotation move, exploring capital structure dynamics, sector context, and broader market relevance in a clear, investor-friendly format.

 Amplia Expands Cancer Research With New Global Collaboration

Amplia Expands Cancer Research With New Global Collaboration

December 19, 2025 12:27 PM AEDT| By Sam

An in-depth look at Amplia Therapeutics’ expanded research collaboration, its cancer pipeline direction, and how advanced preclinical models are shaping future oncology studies.

 Radiopharm Theranostics Responds to ASX Rule Compliance Review

Radiopharm Theranostics Responds to ASX Rule Compliance Review

December 18, 2025 03:05 PM AEDT| By Sam

Radiopharm Theranostics has addressed a listing rule oversight, outlining governance enhancements and external advisory support to strengthen compliance and align future capital activities with ASX requirements.

 Orthocell Reaches Key US Commercial Milestone With Remplir Uptake

Orthocell Reaches Key US Commercial Milestone With Remplir Uptake

December 18, 2025 12:35 PM AEDT| By Sam

Orthocell has reached an early US commercial milestone for Remplir, signalling growing adoption momentum supported by surgeon engagement, hospital access progress, and a disciplined international expansion strategy.

 Regulatory Crossroads Put Telix Under the Biotech Spotlight

Regulatory Crossroads Put Telix Under the Biotech Spotlight

December 17, 2025 08:15 PM AEDT| By Sam

This article explores how regulatory feedback and legal scrutiny reshaped sentiment around Telix, while ongoing clinical and operational progress kept long-term focus alive.

 Understanding Cochlear’s Market Strength and Financial Signals

Understanding Cochlear’s Market Strength and Financial Signals

December 17, 2025 07:37 PM AEDT| By Team Kalkine Media

This article explores how Cochlear’s business model, financial discipline, and global footprint shape market confidence, while explaining key valuation signals in a clear and accessible way.

 CSL Limited Navigates Shifting Market Expectations

CSL Limited Navigates Shifting Market Expectations

December 17, 2025 06:24 PM AEDT| By Sam

This article explores CSL Limited’s evolving business narrative, capital actions, and sector positioning as market focus shifts toward execution, stability, and long-term healthcare demand across the ASX stock market.

 CSL Ltd Overview within the ASX Healthcare Segment and ASX 100

CSL Ltd Overview within the ASX Healthcare Segment and ASX 100

December 17, 2025 04:32 PM AEDT| By Sam

CSL Ltd functions within the healthcare sector, maintains global operations, and holds inclusion in key Australian equity indices supporting market diversity.

 Cancer Drug Progress Reshapes Percheron’s Clinical Journey

Cancer Drug Progress Reshapes Percheron’s Clinical Journey

December 17, 2025 04:20 PM AEDT| By Sam

This article explores how Percheron Therapeutics is reshaping its clinical strategy through oncology research progress, pipeline focus, and broader market relevance within the ASX stock market ecosystem.

 Inside Biotech: Telix and the Weight of Regulatory Uncertainty

Inside Biotech: Telix and the Weight of Regulatory Uncertainty

December 17, 2025 04:05 PM AEDT| By Sam

This article explores how regulatory reviews and legal scrutiny are shaping sentiment around Telix Pharmaceuticals, while pipeline advancement and operational progress continue within the evolving ASX stock market landscape.

 Has Mesoblast’s Share Rally Masked Its Long-Term Story?

Has Mesoblast’s Share Rally Masked Its Long-Term Story?

December 17, 2025 03:21 PM AEDT| By Sam

An in-depth look at Mesoblast’s valuation debate, clinical pipeline outlook, and broader biotech context, exploring how market expectations and fundamentals shape long-term perceptions.

 Biotech Valuation Reset Sparks Fresh Market Debate

Biotech Valuation Reset Sparks Fresh Market Debate

December 17, 2025 12:27 PM AEDT| By Sam

Australia’s biotech sector sees renewed attention as valuation reassessment and improving sentiment highlight long-term potential, even as execution risk continues to shape cautious market expectations.

 How Overseas R&D Recognition Elevates Recce’s Global Strategy

How Overseas R&D Recognition Elevates Recce’s Global Strategy

December 16, 2025 07:24 PM AEDT| By Sam

An in-depth look at how Recce Pharmaceuticals Ltd expands global anti-infective research following overseas R&D recognition, highlighting clinical progress, innovation strategy, and relevance within the ASX stock market.

 Is Sonic Healthcare’s Market Position Drawing Fresh Attention?

Is Sonic Healthcare’s Market Position Drawing Fresh Attention?

December 16, 2025 05:54 PM AEDT| By Sam

This article explores Sonic Healthcare Ltd’s business structure, financial health, and valuation context while assessing how broader healthcare and ASX trends influence its market positioning.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.